» Articles » PMID: 39074163

Understanding Early HIV-1 Rebound Dynamics Following Antiretroviral Therapy Interruption: The Importance of Effector Cell Expansion

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2024 Jul 29
PMID 39074163
Authors
Affiliations
Soon will be listed here.
Abstract

Most people living with HIV-1 experience rapid viral rebound once antiretroviral therapy is interrupted; however, a small fraction remain in viral remission for an extended duration. Understanding the factors that determine whether viral rebound is likely after treatment interruption can enable the development of optimal treatment regimens and therapeutic interventions to potentially achieve a functional cure for HIV-1. We built upon the theoretical framework proposed by Conway and Perelson to construct dynamic models of virus-immune interactions to study factors that influence viral rebound dynamics. We evaluated these models using viral load data from 24 individuals following antiretroviral therapy interruption. The best-performing model accurately captures the heterogeneity of viral dynamics and highlights the importance of the effector cell expansion rate. Our results show that post-treatment controllers and non-controllers can be distinguished based on the effector cell expansion rate in our models. Furthermore, these results demonstrate the potential of using dynamic models incorporating an effector cell response to understand early viral rebound dynamics post-antiretroviral therapy interruption.

Citing Articles

Bistability and bifurcations in HIV-1 infection model with non-monotone responses.

Pradeesh M, Mani P Sci Rep. 2025; 15(1):7265.

PMID: 40025097 PMC: 11873265. DOI: 10.1038/s41598-025-91417-x.


Trade-off between the antiviral and vaccinal effects of antibody therapy in the humoral response to HIV.

Mittal S, Garg A, Desikan R, Dixit N J R Soc Interface. 2024; 21(221):20240535.

PMID: 39626747 PMC: 11614529. DOI: 10.1098/rsif.2024.0535.

References
1.
Fennessey C, Pinkevych M, Immonen T, Reynaldi A, Venturi V, Nadella P . Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. PLoS Pathog. 2017; 13(5):e1006359. PMC: 5433785. DOI: 10.1371/journal.ppat.1006359. View

2.
Chand S, DeMarino C, Gowen A, Cowen M, Al-Sharif S, Kashanchi F . Methamphetamine Induces the Release of Proadhesive Extracellular Vesicles and Promotes Syncytia Formation: A Potential Role in HIV-1 Neuropathogenesis. Viruses. 2022; 14(3). PMC: 8950763. DOI: 10.3390/v14030550. View

3.
Migueles S, Weeks K, Nou E, Berkley A, Rood J, Osborne C . Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol. 2009; 83(22):11876-89. PMC: 2772718. DOI: 10.1128/JVI.01153-09. View

4.
Esmaeilzadeh E, Etemad B, Lavine C, Garneau L, Li Y, Regan J . Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption. Sci Transl Med. 2023; 15(695):eabq4490. PMC: 10576978. DOI: 10.1126/scitranslmed.abq4490. View

5.
de Boer R, Perelson A . Towards a general function describing T cell proliferation. J Theor Biol. 1995; 175(4):567-76. DOI: 10.1006/jtbi.1995.0165. View